Immunocore
PublicImmunocore is now publicly traded
The data on this page reflects Immunocore's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 4, 2021
Last Round
PIPE
Jul 18, 2022
Total Funding Raised
$1.08B
Company Overview
Immunocore is a biotechnology company that develops a novel class of TCR bispecific immunotherapies to treat cancer, infectious diseases, and autoimmune conditions.
Sector
Biotech
AI Layer
Non-AI
Keywords
Immunocore Comparables
Compare Immunocore with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Yellowstone Biosciences | 67% | |
| Normunity | 67% | |
| Crossbow Therapeutics | 64% |
For institutional investors. Book with your work email.
Immunocore Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Jul 18, 2022 | ||||
| Private Placement | Feb 5, 2021 | ||||
| IPO | Feb 4, 2021 | ||||
| Series C | Jan 11, 2021 | ||||
| Debt | Jan 11, 2021 | ||||
Series B | Mar 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immunocore Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fidelity Management & Research Company | Series A |
| CCB International | Series B |
| Woodford Investment Management | Series A |
| The Bill & Melinda Gates Foundation Trust | Series B, Convertible Debt, Private Placement |
| JDRF | Series B |
| RTW Investments | Series A, Series B |
| Terra Magnum Capital Partners | Series B |
For institutional investors. Book with your work email.
Immunocore Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.